Valganciclovir 450mg Tablet


Each film coated tablet contains:
Valganciclovir hydrochloride USP eq. to Valganciclovir 450mg

[ We were the "first company to Launch Valganciclovir Hcl USP 450mg tablets (CMV disease / organ transplant drug) in India as Non Infringing product against ROCHE Patent and thereafter started manufacturing PROTHYMO(Sanofi), VEGACYTE (Panacea), VALGACEL (Intas), VALCHEK (La Renon), CMVee (RPG), VALNICHE (Alniche) ]

Product Profile

Valganciclovir, a pro-drug of antiviral, Gancilcovir which, after oral administration, is rapidly converted to ganciclovir by intestinal and hepatic esterases. The virustatic activity of Ganciclovir is due to inhibition of viral DNA synthesis by: (a) competitive inhibition of incorporation of deoxyguanosine-triphosphate into DNA by viral DNA polymerase, and (b) incorporation of ganciclovir triphosphate into viral DNA causing termination of, or very limited, further viral DNA elongation.

It is rapidly and extensively converted to the active ingredient Ganciclovir. Its bioavailability is 10-fold higher than from oral Gancilcovir.


  • Prevention of CMV Disease in Transplant recipients ; prevention of CMV disease in kidney, heart, and kidney-pancreas transplant recipients at high risk (CMV-seronegative recipient/CMV-seropositive donor).
  • Cytomegalovirus (CMV) Retinitis and secondary prophylaxis of CMV retinitis in HIVinfected
©2015 Pharose Remedies Limited. All rights reserved